News & Perspective

Oct 26, 2007

Oct 26, 2007

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Aug 06, 2008

Aug 06, 2008

FDA approvals clear way for flu vaccine marketing

Editor's note: This story was updated Aug 7 to include information about the start of influenza vaccine shipments by Novartis.

(CIDRAP News) – The six companies that make influenza vaccine for the US market have won federal approval for their version of this year's vaccine, in which all three flu strains used in last year's product have been replaced, the Food and Drug Administration (FDA) announced yesterday.

Sep 20, 2013

Sep 20, 2013

News Scan for Sep 20, 2013

Anthrax antitoxin orders
H7N7 risk assessment
Poliovirus in Palestine
Malaria drug ban

Jan 08, 2014

Jan 08, 2014

News Scan for Jan 08, 2014

Liquid Tamiflu shortage
Measles in Europe
India almost 3 years polio-free

Feb 25, 2015

Feb 25, 2015

News Scan for Feb 25, 2015

New MERS case, study
Measles surge in Europe
Group B mening vaccine

Feb 14, 2018

Feb 14, 2018

Stewardship / Resistance Scan for Feb 14, 2018

MCR-1 in Italy, Hong Kong
Fast track for ESBL inhibitor
MDR-TB drug combo

Pages

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»